ZA200504820B - Combinations of growth regulaitng factors and hormones for the treatment of neoplasia - Google Patents

Combinations of growth regulaitng factors and hormones for the treatment of neoplasia Download PDF

Info

Publication number
ZA200504820B
ZA200504820B ZA200504820A ZA200504820A ZA200504820B ZA 200504820 B ZA200504820 B ZA 200504820B ZA 200504820 A ZA200504820 A ZA 200504820A ZA 200504820 A ZA200504820 A ZA 200504820A ZA 200504820 B ZA200504820 B ZA 200504820B
Authority
ZA
South Africa
Prior art keywords
coupled
carrier protein
egf
antibodies
humanized
Prior art date
Application number
ZA200504820A
Other languages
English (en)
Inventor
Eddy Bover Fuentes
Eulogio Pimental Vazquez
Franklin Fuentes Aguilar
Lesvia Calzada Aguilera
Yovisleidys Lopez Saez
Glay Chinea Santiago
Roberto Basulto Baker
Barranco Jesus A M N Junco
Hector Hernandez Dominguez
Nieto Gerardo E Gullien
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of ZA200504820B publication Critical patent/ZA200504820B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001131Epidermal growth factor [EGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001134Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001135Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Silicon Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200504820A 2002-12-27 2006-01-16 Combinations of growth regulaitng factors and hormones for the treatment of neoplasia ZA200504820B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Publications (1)

Publication Number Publication Date
ZA200504820B true ZA200504820B (en) 2006-03-29

Family

ID=40091671

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200504820A ZA200504820B (en) 2002-12-27 2006-01-16 Combinations of growth regulaitng factors and hormones for the treatment of neoplasia

Country Status (17)

Country Link
US (1) US20060193853A1 (ru)
EP (1) EP1576965B1 (ru)
JP (1) JP4384054B2 (ru)
KR (1) KR100712426B1 (ru)
CN (1) CN1732017B (ru)
AT (1) ATE445410T1 (ru)
AU (1) AU2003291915B2 (ru)
BR (1) BR0317506A (ru)
CA (1) CA2507470C (ru)
CU (1) CU23204A1 (ru)
DE (1) DE60329710D1 (ru)
ES (1) ES2334344T3 (ru)
MX (1) MXPA05006979A (ru)
MY (1) MY140305A (ru)
RU (1) RU2321422C2 (ru)
WO (1) WO2004058297A1 (ru)
ZA (1) ZA200504820B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473530B1 (en) 2009-09-03 2015-04-22 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
MX2012013702A (es) * 2010-05-26 2013-03-21 Univ Minnesota Anticuerpos anti-cd133 de fragmento variable de cadena individual y usos de los mismos.
CN104004762B (zh) * 2014-05-20 2016-03-30 南京医科大学附属南京儿童医院 Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用
KR20190117541A (ko) * 2017-01-20 2019-10-16 이뮨 시스템 레귤레이션 홀딩 에이비 신규 화합물 (이뮤노렐린)
US10988754B2 (en) 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
EP4183417A1 (en) * 2019-09-12 2023-05-24 Hexamer Therapeutics, Inc. An immunotherapeutic for prostate cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DK0666868T4 (da) * 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22627A1 (es) * 1996-12-17 2000-12-22 Ct Ingenieria Genetica Biotech Preparado vacunal para la inmuno-castración reversible de mamíferos
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
US8026229B2 (en) * 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates

Also Published As

Publication number Publication date
DE60329710D1 (de) 2009-11-26
CN1732017B (zh) 2011-12-21
RU2321422C2 (ru) 2008-04-10
EP1576965A1 (en) 2005-09-21
JP4384054B2 (ja) 2009-12-16
KR20050089016A (ko) 2005-09-07
CN1732017A (zh) 2006-02-08
BR0317506A (pt) 2005-11-16
CU23204A1 (es) 2007-05-18
AU2003291915B2 (en) 2008-12-04
AU2003291915A1 (en) 2004-07-22
JP2006514036A (ja) 2006-04-27
ATE445410T1 (de) 2009-10-15
MY140305A (en) 2009-12-31
US20060193853A1 (en) 2006-08-31
KR100712426B1 (ko) 2007-04-27
WO2004058297A1 (es) 2004-07-15
CA2507470C (en) 2010-11-09
RU2005123813A (ru) 2006-01-27
CA2507470A1 (en) 2004-07-15
EP1576965B1 (en) 2009-10-14
MXPA05006979A (es) 2005-08-16
ES2334344T3 (es) 2010-03-09

Similar Documents

Publication Publication Date Title
Alexander et al. Effects of bombesin on growth of human small cell lung carcinoma in vivo
EP0181236B1 (en) Lhrh analogues useful in stimulating anti-lhrh antibodies and vaccines containing such analogues
JP5200269B2 (ja) 胃腸癌治療用の免疫学的方法
US5573767A (en) Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals, vaccines which are usable in this method, new peptide, in particular for producing these vaccines and vaccination kit relating thereto
JPH10512881A (ja) 成長ホルモン放出ホルモンの新規な非常に効力のあるアゴニスト
ZA200504820B (en) Combinations of growth regulaitng factors and hormones for the treatment of neoplasia
US9364524B2 (en) Pharmaceutical composition using gonadotropin-releasing hormone (GNRH) combined variants as immunogen
JP2002538219A (ja) 癌及び高増殖性疾患治療用の組成物及び方法
EP0284406A1 (en) Biologically active molecules
Lamberts et al. Somatostatin analogs: future directions
JP2002515457A (ja) 腫瘍治療のための併用療法
JP2003532740A (ja) キメラペプチド免疫原
Fuentes et al. Active component of a GnRH based vaccine binds to natural GnRH receptors in Dunning R3327-G cell line and human prostate carcinoma vesicles.
Junco et al. Induction of androgenic ablation and inhibition of prostate hormone-sensitive tumors by immunization with the GnRHm1-TT synthetic peptide adjuvated in VSSP
NZ215999A (en) Vaccine for inducing antibodies to lhrh
CA2055619A1 (en) Grf peptides